Zenotech Laboratories

Zenotech Laboratories Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -201.67. In the previous year, Cash Conversion Cycle (CCC) was -45.02 — a change of 347.98% (lower).

Cash Conversion Cycle

-201.67

YoY

347.98%

Last updated:

Cash Conversion Cycle (CCC) of Zenotech Laboratories is 2026 -201.67 . Cash Conversion Cycle (CCC) of Zenotech Laboratories was 2025 -45.02 . It decreases by 347.98% lower compared to the previous year.

The Zenotech Laboratories Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
-481.31 INR
Jan 1, 2020
-656.81 INR
Jan 1, 2021
-210.19 INR
Jan 1, 2022
-236.85 INR
Jan 1, 2023
-143.69 INR
Jan 1, 2024
-69.93 INR
Jan 1, 2025
-45.02 INR
Jan 1, 2026
-201.67 INR
The Zenotech Laboratories Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-201.67+347.98%
-45.02-35.62%
-69.93-51.33%
-143.69-39.33%
-236.85+12.68%
-210.19-68.00%
-656.81+36.46%
-481.31-31.51%
-702.72-23.67%
-920.68+118.85%
-420.69-7,438.31%
5.73-83.05%
33.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Cash Conversion Cycle (CCC) of Zenotech Laboratories is -201.67 in 2026.

Cash Conversion Cycle (CCC) of Zenotech Laboratories changed from -45.02 to -201.67, representing a 347.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories